Spectrum Pharmaceuticals (SPPI) Says Additional Satraplatin Efficacy Data From Phase 3 SPARC Trial Presented at Annual Meeting
Tweet Send to a Friend
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) announced the presentation of additional satraplatin data from the double-blind, randomized, placebo-controlled Phase 3 registrational ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
